183 related articles for article (PubMed ID: 35795681)
21. Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells.
Mariotti FR; Ingegnere T; Landolina N; Vacca P; Munari E; Moretta L
Front Immunol; 2023; 14():1229341. PubMed ID: 37638041
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1.
Ramaswamy M; Kim T; Jones DC; Ghadially H; Mahmoud TI; Garcia A; Browne G; Zenonos Z; Puplampu-Dove Y; Riggs JM; Bhat GK; Herbst R; Schofield DJ; Carlesso G
Cancer Immunol Res; 2022 Feb; 10(2):200-214. PubMed ID: 34937728
[TBL] [Abstract][Full Text] [Related]
23. [Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].
Liu YF; He PC; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1317-1322. PubMed ID: 30295244
[TBL] [Abstract][Full Text] [Related]
24. Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.
Bodhankar S; Chen Y; Lapato A; Vandenbark AA; Murphy SJ; Offner H
Front Cell Neurosci; 2014; 8():228. PubMed ID: 25157219
[TBL] [Abstract][Full Text] [Related]
25. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
[TBL] [Abstract][Full Text] [Related]
26. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
27. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
28. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
[TBL] [Abstract][Full Text] [Related]
30. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
31. Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8
Sierra JM; Secchiari F; Nuñez SY; Iraolagoitia XLR; Ziblat A; Friedrich AD; Regge MV; Santilli MC; Torres NI; Gantov M; Trotta A; Ameri C; Vitagliano G; Pita HR; Rico L; Rovegno A; Richards N; Domaica CI; Zwirner NW; Fuertes MB
Front Immunol; 2021; 12():745939. PubMed ID: 34616407
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
Okiyama N; Katz SI
J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
[TBL] [Abstract][Full Text] [Related]
33. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
Zhou Q; Munger ME; Highfill SL; Tolar J; Weigel BJ; Riddle M; Sharpe AH; Vallera DA; Azuma M; Levine BL; June CH; Murphy WJ; Munn DH; Blazar BR
Blood; 2010 Oct; 116(14):2484-93. PubMed ID: 20570856
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
35. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
Zhang L; Gajewski TF; Kline J
Blood; 2009 Aug; 114(8):1545-52. PubMed ID: 19417208
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
[TBL] [Abstract][Full Text] [Related]
38. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.
Shi XL; Mancham S; Hansen BE; de Knegt RJ; de Jonge J; van der Laan LJ; Rivadeneira F; Metselaar HJ; Kwekkeboom J
J Hepatol; 2016 Jun; 64(6):1274-82. PubMed ID: 26941095
[TBL] [Abstract][Full Text] [Related]
39. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
40. Programmed death-1 targeting can promote allograft survival.
Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]